Briefing
Beyond trials
How real-world data is transforming autoimmune research
Autoimmune diseases impact millions of Americans, with conditions like rheumatoid arthritis, lupus, psoriasis, and Crohn’s disease on the rise. Traditional trials and registries fall short in capturing long-term outcomes and real-world treatment patterns. Truveta Data provides a regulatory-grade, nationally representative dataset from over 120 million patients—integrating EHR data, clinical notes, SDoH, imaging, claims, and mortality data. This enables researchers to study autoimmune disease with unprecedented scale, depth, and diversity.
Recent insights from Truveta demonstrate how biosimilar switching surged after a major formulary change, highlighting how payer policies shape treatment adoption. Truveta’s AI-powered analysis of clinical notes and images reveals patient-level disease severity, treatment history, and quality-of-life impacts, helping researchers monitor therapy effectiveness over time.
Key takeaways:
- How formulary changes drive biosimilar switching trends in autoimmune care.
- Why AI-powered clinical notes enable richer analysis of disease progression and treatment response.
- How real-world data supports post-market safety, label expansion, and payer strategy.
